An Austrian study led by MedUni Vienna showed a partial or complete regression of brain metastasis in breast cancer patients after treatment with trastuzumab deruxtecan (T-Dxd).
Read the full post on Becker's Hospital Review - Healthcare News
Read the full post on Becker's Hospital Review - Healthcare News